H.C. Wainwright downgraded Day One Biopharmaceuticals (DAWN) to Neutral from Buy with a price target of $21.50, down from $22, after the company announced an agreement under which Servier will acquire it for $21.50 per share in cash.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharma Earnings Call Highlights Ojemda Surge
- Hold Rating on Day One Biopharmaceuticals as Servier’s $2.5 Billion Takeout Caps Upside at $21.50 Target
- Midday Fly By: Rising oil prices, falling employment sink stocks
- Day One Biopharmaceuticals downgraded to Hold from Buy at TD Cowen
- Day One Biopharmaceuticals downgraded to Neutral from Overweight at Piper Sandler